Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Enzyme-Linked Immunosorbent Assay01:33

Enzyme-Linked Immunosorbent Assay

18.4K
In 1971, Peter Perlman and Eva Engvall developed an Enzyme-linked immunosorbent assay (ELISA or EIA). ELISA differs from western blot in that the assays are conducted in microtiter plates or in vivo rather than on an absorbent membrane.
There are many different types of ELISAs, but they all involve an antibody molecule whose constant region binds an enzyme, leaving the variable region free to bind its specific antigen.  Enzyme-substrate reaction allows the antigen to be visualized or...
18.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Connectomic evidence that ordered activity drives neuromuscular network formation.

Nature neuroscience·2026
Same author

Adolescent social isolation induces persistent impairments in emotional discrimination and helping behavior.

eNeuro·2026
Same author

Development and internal validation of a nomogram for predicting 30-day mortality in older patients with hemophagocytic lymphohistiocytosis.

BMC geriatrics·2026
Same author

Preoperative Prediction of Microvascular Invasion in Hepatocellular Carcinoma: A Chinese Retrospective Multicenter Study Based on Global Meta-Analysis.

Cancer medicine·2026
Same author

Dissociating the Hallucinogenic and Neuroplastic Effects of Psilocybin.

bioRxiv : the preprint server for biology·2026
Same author

NSUN6 overexpression promotes malignant phenotypes and predicts poor prognosis in clear cell renal cell carcinoma.

Cancer cell international·2026

Related Experiment Video

Updated: Mar 20, 2026

Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets
11:03

Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets

Published on: February 10, 2020

7.8K

Hemolysis Affects C-Peptide Immunoassay.

Zhi-Qi Wu1, Ju Lu1, Hua-Guo Xu2

  • 1Department of Laboratory Medicine, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China.

Journal of Clinical Laboratory Analysis
|May 28, 2016
PubMed
Summary
This summary is machine-generated.

Hemolysis significantly impacts C-peptide measurements, affecting its accuracy as a marker for insulin secretion. An individualized correction equation was developed to ensure accurate C-peptide results from hemolyzed samples.

Keywords:
C-peptidehemolysishypoglycemiaindividualized correction

More Related Videos

Electrochemiluminescence Assays for Human Islet Autoantibodies
09:15

Electrochemiluminescence Assays for Human Islet Autoantibodies

Published on: March 23, 2018

16.2K
Detection and Quantification of Calcitonin Gene-Related Peptide CGRP in Human Plasma Using a Modified Enzyme-Linked Immunosorbent Assay
07:14

Detection and Quantification of Calcitonin Gene-Related Peptide CGRP in Human Plasma Using a Modified Enzyme-Linked Immunosorbent Assay

Published on: June 16, 2023

3.5K

Related Experiment Videos

Last Updated: Mar 20, 2026

Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets
11:03

Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets

Published on: February 10, 2020

7.8K
Electrochemiluminescence Assays for Human Islet Autoantibodies
09:15

Electrochemiluminescence Assays for Human Islet Autoantibodies

Published on: March 23, 2018

16.2K
Detection and Quantification of Calcitonin Gene-Related Peptide CGRP in Human Plasma Using a Modified Enzyme-Linked Immunosorbent Assay
07:14

Detection and Quantification of Calcitonin Gene-Related Peptide CGRP in Human Plasma Using a Modified Enzyme-Linked Immunosorbent Assay

Published on: June 16, 2023

3.5K

Area of Science:

  • Clinical Chemistry
  • Biomarker Analysis
  • Diabetes Mellitus Research

Background:

  • C-peptide is a crucial marker for insulin secretion and is implicated in coronary artery disease (CAD) development in type 2 diabetes mellitus (T2DM).
  • Previous research suggested C-peptide assays are unaffected by hemolysis, but routine practice revealed otherwise.
  • Hemolysis was observed to negatively interfere with C-peptide measurements in laboratory settings.

Purpose of the Study:

  • To investigate the impact of hemolysis on C-peptide assay accuracy.
  • To develop and validate an individualized correction equation for C-peptide measurements in hemolyzed samples.
  • To improve the reliability of C-peptide testing in routine clinical practice.

Main Methods:

  • Studied hemolysis effects by adding lysed red blood cells to serum samples.
  • Derived an individualized correction equation based on hemolysis parameters.
  • Evaluated the derived equation's performance using artificially hemolyzed samples.

Main Results:

  • C-peptide concentration demonstrated a decrease with increased hemolysis degree and duration.
  • An individualized correction equation (C-Pcorr = C-Pmeas /(0.969-1.5Hbserum/plasma -5.394 ×10-5 Time)) was established.
  • The equation effectively corrects for C-peptide measurement bias caused by hemolysis.

Conclusions:

  • Hemolysis adversely affects C-peptide measurements.
  • The developed individualized correction equation enables accurate reporting of C-peptide in hemolyzed samples across various hemolysis degrees.
  • Implementing this correction enhances diagnostic accuracy and prevents suboptimal treatment decisions.